SCHEMBL758877

SCHEMBL758877

CNc1cn2ccccc2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.47
PTGS2 P35354 1/20 0.47
KDM4E B2RXH2 7/20 0.46
ALDH1A1 P00352 5/20 0.46
HPGD P15428 3/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
MAPT P10636 1/20 0.46
RAB9A P51151 13/20 0.45
NPC1 O15118 11/20 0.45
PKM P14618 3/20 0.45
EPHX2 P34913 1/20 0.45
POLB P06746 1/20 0.45
SMN1; SMN2 Q16637 4/20 0.44
GFER P55789 2/20 0.44
ALOX12 P18054 1/20 0.44
NFKB1 P19838 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
HDAC6 Q9UBN7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17962528 0.84 PTGS1 (0.50) PTGS1PTGS2KDM4EALDH1A1HPGD
SCHEMBL11989037 0.80 PTGS1 (0.44) PTGS1PTGS2KDM4EALDH1A1HPGD
SCHEMBL1495230 0.78 RAB9A (0.53) PTGS1PTGS2KDM4EALDH1A1HPGD
SCHEMBL6285527 0.77 PTGS1 (0.47) PTGS1PTGS2KDM4EALDH1A1HPGD
SCHEMBL2289469 0.76 MAPT (0.44) PTGS1PTGS2KDM4EALDH1A1HPGD
SCHEMBL28842853 0.76 TLR9 (0.44) KDM4EALDH1A1HPGDRAB9ANPC1
SCHEMBL913680 0.75 PTGS1 (0.58) PTGS1PTGS2KDM4EALDH1A1HPGD
SCHEMBL24834491 0.74 NPC1 (0.52) KDM4EALDH1A1HPGDMAPTRAB9A
SCHEMBL5670922 0.74 TLR7 (0.48) KDM4EALDH1A1HPGDCYP1A2CYP3A4
SCHEMBL171008 0.74 PTGS1 (0.52) PTGS1PTGS2KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11319303-B2 Compound used as autophagy regulator, and preparation method therefor and uses thereof Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) 2022-05-03 US disclosed
EP-3943490-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS Mission Therapeutics Limited (GB) 2022-01-26 EP disclosed
US-11066365-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2021-07-20 US disclosed
EP-3277677-B9 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LTD (GB) 2021-07-14 EP disclosed
US-11053198-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2021-07-06 US disclosed
EP-3842427-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS Mission Therapeutics Limited (GB) 2021-06-30 EP disclosed
EP-3277677-B1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LTD (GB) 2021-02-24 EP disclosed
WO-2020163554-A1 IL-17A MODULATORS AND USES THEREOF DICE ALPHA, INC. (US) 2020-08-13 WO disclosed
US-10689345-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors MISSION THERAPEUTICS LIMITED (GB) 2020-06-23 US disclosed
US-20200190066-A1 COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) 2020-06-18 US disclosed
US-20190284138-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2019-09-19 US disclosed
US-20190270708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2019-09-05 US disclosed
US-10343992-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors Missions Therapeutics Limited (GB) 2019-07-09 US disclosed
US-20180086708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2018-03-29 US disclosed
US-20180086708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2018-03-29 US disclosed
US-20130079325-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS ALLEN JENNIFER R (US) 2013-03-28 US disclosed
US-20120053345-A1 Indazole Compounds ABBOTT LABORATORIES (US) 2012-03-01 US disclosed
WO-2008067928-A1 UV ABSORBING COMPOSITIONS CONTAINING A PYRROLYLTRIAZINE ISDIN S.A. (ES) 2008-06-12 WO disclosed
US-7368566-B2 Process and intermediates for preparing benzazepines SMITHKLINE BEECHAM CORPORATION (US) 2008-05-06 US disclosed
US-20070149505-A1 Method of Inhibiting Adhesion Formation SMITHKLINE BEECHAM CORPORATION 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11066365-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 PTGS1 2473/4885PTGS2 3233/4885KDM4E 364/4885
US-11319303-B2 Compound used as autophagy regulator, and preparation method therefor and uses thereof ATG7, SQSTM1, BECN1 PTGS1 3079/4885PTGS2 3463/4885KDM4E 2846/4885
US-20130079325-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS PDE7A, PDE9A, PDE10A PTGS1 1824/4885PTGS2 3133/4885KDM4E 1314/4885
US-10343992-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 PTGS1 2295/4885PTGS2 3084/4885KDM4E 304/4885
US-11053198-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 PTGS1 2295/4885PTGS2 3084/4885KDM4E 304/4885
US-20070149505-A1 Method of Inhibiting Adhesion Formation VCAM1, EPCAM, ADGRF1 PTGS1 1004/4885PTGS2 1176/4885KDM4E 4394/4885
US-20190284138-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 PTGS1 2473/4885PTGS2 3233/4885KDM4E 364/4885
US-20200190066-A1 COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF ATG7, SQSTM1, BECN1 PTGS1 3079/4885PTGS2 3463/4885KDM4E 2846/4885
US-20180086708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 PTGS1 2295/4885PTGS2 3084/4885KDM4E 304/4885
US-10689345-B2 1-cyano-pyrrolidine compounds as USP30 inhibitors USP30, USP20, USP10 PTGS1 2295/4885PTGS2 3084/4885KDM4E 304/4885
US-20120053345-A1 Indazole Compounds CYP3A43, CYP3A7, UGT1A1 PTGS1 1257/4885PTGS2 1919/4885KDM4E 3676/4885
US-20190270708-A1 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS USP30, USP20, USP10 PTGS1 2295/4885PTGS2 3084/4885KDM4E 304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.